Credit Suisse Raises Numbers on Salix Pharmaceuticals (SLXP) Citing Higher IBS Revenues
Tweet Send to a Friend
Credit Suisse raised estimates and their price target on Outperform-rated Salix Pharmaceuticals (NASDAQ: SLXP) due to higher IBS revenue.
This article: 171 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 171 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
